Motif Bio plc Release: Amphion Innovations plc
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, notes the announcement this morning by Amphion Innovations plc (“Amphion”), that Amphion has pledged 14,906,145 ordinary shares of 1 pence each in the capital of Motif Bio as security to a draw-down of an additional tranche of Amphion’s loan facility.
Graham Lumsden, CEO of Motif Bio, commented: “We welcome Amphion’s continued commitment as a shareholder in Motif Bio.”
Graham Lumsden, CEO of Motif Bio, commented: “We welcome Amphion’s continued commitment as a shareholder in Motif Bio.”